Noninvasive Targeted Transcranial Neuromodulation via Focused Ultrasound Gated Drug Release from Nanoemulsions
Year: 2017
Type: article
Abstract: Targeted, noninvasive neuromodulation of the brain of an otherwise awake subject could revolutionize both basic and clinical neuroscience. Toward this goal, we have developed nanoparticles that allow noninvasive uncaging of a neuromodulatory drug, in this case the small molecule anesthetic propofol, upon the application of focused ultrasound. These nanoparticles are composed of biodegradable and biocompatible constituents and are activated using sonication parameters that are readily achievable by current clinical transcranial focused ultrasound systems. These particles are potent enough that their activation can silence seizures in an acute rat seizure model. Notably, there is no evidence of brain parenchymal damage or blood-brain barrier opening with their use. Further development of these particles promises noninvasive, focal, and image-guided clinical neuromodulation along a variety of pharmacological axes.
Source: Nano Letters
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funders: National Science Foundation, Philips, Achievement Rewards for College Scientists Foundation, National Institutes of Health, Foundation of the American Society of Neuroradiology, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute of Child Health and Human Development, Division of Graduate Education, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G254888587, G3655617666, G4183297229, G4247100892, G4447472125, G4621788029, Cancer-specific nanoparticle-mediated gene therapy to treat hepatocellular carcinoma, G556320034, Gene Delivery Nanoparticles to Treat Glioblastoma, Graduate Research Fellowship Program (GRFP), G9000048674, G9000299654, G9000345188
OpenAlex ID: W2573609557